GlassScriptPhysician profile
Kent D Childs
NPI 1427022714
$22,723.88
in general payments reported to CMS, 2019-2025
42 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $171 · 2021: $743 · 2022: $1,223 · 2023: $1,011 · 2024: $8,054 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,884 · Food and Beverage: $2,822 · Travel and Lodging: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,884.00 |
| Food and Beverage | $2,821.61 |
| Travel and Lodging | $2,099.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15,636.56 | 2024-2025 | Zurzuvae |
| Sage Therapeutics, LLC | $1,798.89 | 2023-2025 | Zurzuvae |
| Intuitive Surgical, INC. | $926.51 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $620.57 | 2023-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $515.02 | 2020-2023 | Ova1 |
| Biohaven Pharmaceutical Holding Company LTD. | $499.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $372.11 | 2020-2021 | |
| Astellas Pharma US INC | $365.25 | 2022-2025 | Veozah, Vesicare, Myrbetriq |
| Abbvie INC. | $307.86 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Pfizer INC. | $239.31 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $140.29 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.62 | 2019-2025 | |
| Myovant Sciences INC. | $106.36 | 2022 | |
| Channel Medsystems, INC. | $78.74 | 2023 | |
| Lsi Solutions INC | $75.61 | 2020-2023 | Running Device |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $72.88 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $66.66 | 2019-2022 | |
| Exeltis, USA INC. | $64.02 | 2022-2025 | Slynd |
| Coloplast Corp | $62.32 | 2024 | |
| Organon LLC | $56.97 | 2022-2025 | Nexplanon |
| Medtronic, INC. | $54.94 | 2025 | Ligasure |
| Boston Scientific Corporation | $50.76 | 2024-2025 | Axonics, Solyx Sis System, Upsylon |
| Conmed Corporation | $44.44 | 2019 | |
| Daiichi Sankyo INC. | $43.52 | 2019-2022 | |
| Baxter Healthcare | $41.91 | 2025 | Perclot |
| Supernus Pharmaceuticals, INC. | $41.14 | 2025 | Qelbree |
| Avion Pharmaceuticals | $38.56 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.59 | 2022 | |
| Allergan, INC. | $26.31 | 2019 | |
| Coopersurgical, INC. | $25.93 | 2021 | |
| Exact Sciences Corporation | $22.11 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $21.67 | 2024 | Zepbound |
| Lupin INC. | $20.86 | 2019 | |
| Axsome Therapeutics, INC. | $18.34 | 2025 | Symbravo |
| Solventum Corporation | $17.68 | 2025 | Prevena |
| Covidien LP | $16.67 | 2019 | |
| Caldera Medical, INC | $16.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.87 | 2022 | |
| Merck Sharp & Dohme LLC | $13.84 | 2019 | |
| Evofem Biosciences, INC. | $12.86 | 2022 | |
| Scynexis, INC. | $12.72 | 2022 | |
| Mylan Pharmaceuticals INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.